"FDA and DEA Urge Drugmakers to Address Prescription Stimulant Shortage with Increased Manufacturing"

The FDA and DEA are urging drugmakers to increase manufacturing of prescription stimulants to address the ongoing shortage in the US. The shortage, which includes drugs like Adderall used to treat ADHD, has persisted for nearly a year. Factors contributing to the shortage include a surge in prescriptions and manufacturing delays. The DEA is asking manufacturers to relinquish any unused quota so it can be redistributed. The agencies also highlight the need for appropriate diagnosis and treatment of ADHD, including alternative options. The FDA tracks shortages on its website, with estimated recovery dates ranging from this summer to December.